Skip to main content

Epoch Biosciences Sells Specialty Oligo Business to Eurogentec

NEW YORK, May 28 - Epoch Biosciences of Bothell, Wash., today announced the sale of its specialty oligonucleotide business to Liege, Belgium-based Eurogentec.

 

The sale, for $1.4 million in cash, is expected to close May 30. Epoch will transfer its customer base, manufacturing equipment, and inventory to Eurogentec and the two companies will include North America in an existing supply agreement that allows Eurogentec to sell custom oligonucleotides that include Epoch dyes and non-fluorescent quenchers.

 

Epoch said that the sale will allow it to focus on its MGB Eclipse probe systems business and will help the company enter the diagnostics market later this year. The company will record a loss of $3 million on the transaction, taking a non-cash write-off for inventory, equipment, and other assets.

 

Epoch purchased the business, known as Synthetic Genetics, a division of Immune Complex Corp., in November 2000 for $2.6 million to provide manufacturing capacity for the TaqMan MGB probe products marketed by Applied Biosystems.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.